Literature DB >> 29904289

Identifying suspected familial chylomicronemia syndrome.

Ronak Rengarajan1, Peter A McCullough1,2,3,4,5, Anima Chowdhury6, Kristen M Tecson2,3.   

Abstract

Familial chylomicronemia syndrome (FCS) is a rare lipid disorder posing significant clinical burdens on patients. Due to its rarity, variety of presentations, and lack of universal diagnostic criteria, patients see an average of five physicians before diagnosis. We screened adults for a triglyceride level ≥1000 mg/dL from September 2015 to September 2016 and a history of pancreatitis and performed a thorough chart review on those who met the criteria. An adjudication panel used a definition that also called for supportive information including history of hypertriglyceridemia or family history of pancreatitis/hypertriglyceridemia. Among 297,891 adults with laboratory values available, 334 (0.11%) had triglyceride levels ≥1000 mg/dL, and 30 (9%) of those had pancreatitis. Most of these 30 patients were male (73%), had diabetes (90%), were taking a fibrate (93%), and were taking a statin (80%). The average body mass index was 32.5 ± 4.5 kg/m2. Six cases were ruled out, primarily due to substance abuse and/or isolated pancreatitis. Of the 24 suspected FCS cases, the average maximum triglyceride level was 3085 ± 1211 mg/dL. Electronic screening methods based solely on triglycerides ≥1000 mg/dL and pancreatitis eliminated 99.99% of the population, enabling the adjudication panel to focus on 30 cases. In 24 cases, FCS could not be ruled out; hence, the prevalence of FCS may be as high as 1 in 12,413.

Entities:  

Keywords:  Chylomicrons; chylomicronemia syndrome; diagnostic tools; familial hypertriglyceridemia; pancreas; pancreatitis; triglycerides

Year:  2018        PMID: 29904289      PMCID: PMC5997083          DOI: 10.1080/08998280.2018.1463784

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN: 0899-8280


  17 in total

Review 1.  Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency.

Authors:  Daniel Gaudet; Janneke de Wal; Karine Tremblay; Stéphane Déry; Sander van Deventer; Andreas Freidig; Diane Brisson; Julie Méthot
Journal:  Atheroscler Suppl       Date:  2010-04-27       Impact factor: 3.235

2.  A mutation in the human lipoprotein lipase gene as the most common cause of familial chylomicronemia in French Canadians.

Authors:  Y Ma; H E Henderson; V Murthy; G Roederer; M V Monsalve; L A Clarke; T Normand; P Julien; C Gagné; M Lambert
Journal:  N Engl J Med       Date:  1991-06-20       Impact factor: 91.245

3.  Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association.

Authors:  Michael Miller; Neil J Stone; Christie Ballantyne; Vera Bittner; Michael H Criqui; Henry N Ginsberg; Anne Carol Goldberg; William James Howard; Marc S Jacobson; Penny M Kris-Etherton; Terry A Lennie; Moshe Levi; Theodore Mazzone; Subramanian Pennathur
Journal:  Circulation       Date:  2011-04-18       Impact factor: 29.690

4.  Familial chylomicronemia syndrome- an uncommon cause of acute pancreatitis with encephalopathy.

Authors:  Sunil Kumar Kota; Siva Krishna Kota; Sruti Jammula; Kirtikumar D Modi
Journal:  Indian J Gastroenterol       Date:  2012-09

5.  Long-Term Costs and Consequences of Patients with Familial Chylomicronemia Syndrome - A Simulation Model Approach.

Authors:  F Lin; S Thomas; F Calado; J Clegg
Journal:  Value Health       Date:  2014-10-26       Impact factor: 5.725

6.  The burden of familial chylomicronemia syndrome from the patients' perspective.

Authors:  Andres Gelrud; Karren R Williams; Andrew Hsieh; Andrea R Gwosdow; Alan Gilstrap; Alan Brown
Journal:  Expert Rev Cardiovasc Ther       Date:  2017-09-11

7.  Primary lipoprotein-lipase-activity deficiency: clinical investigation of a French Canadian population.

Authors:  C Gagné; L D Brun; P Julien; S Moorjani; P J Lupien
Journal:  CMAJ       Date:  1989-02-15       Impact factor: 8.262

8.  The burden of familial chylomicronemia syndrome: interim results from the IN-FOCUS study.

Authors:  Michael Davidson; Michael Stevenson; Andrew Hsieh; Zahid Ahmad; Caroline Crowson; Joseph L Witztum
Journal:  Expert Rev Cardiovasc Ther       Date:  2017-04-04

Review 9.  Balancing Low-density Lipoprotein Cholesterol Reduction and Hepatotoxicity With Lomitapide Mesylate and Mipomersen in Patients With Homozygous Familial Hypercholesterolemia.

Authors:  Jane I Won; Jun Zhang; Kristen M Tecson; Peter A McCullough
Journal:  Rev Cardiovasc Med       Date:  2017       Impact factor: 2.930

10.  Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome.

Authors:  Charles Daniel Meyers; Karine Tremblay; Ahmed Amer; Jin Chen; Liewen Jiang; Daniel Gaudet
Journal:  Lipids Health Dis       Date:  2015-02-18       Impact factor: 3.876

View more
  1 in total

1.  Case report of one month and 15 days old baby with type V hyperlipoproteinemia (HLP).

Authors:  Shabnam Dildar; Tahir Sultan Shamsi
Journal:  BMC Endocr Disord       Date:  2020-02-11       Impact factor: 2.763

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.